Sabbatini M, Ruggiero G, Palatucci A T, Rubino V, Federico S, Giovazzino A, Apicella L, Santopaolo M, Matarese G, Galgani M, Terrazzano G
Dipartimento di Sanità Pubblica, DH di Nefrologia e Trapianto di Rene, Università di Napoli 'Federico II', Napoli, Italy.
Dipartimento di Scienze Mediche Traslazionali, Università di Napoli 'Federico II', Napoli, Italy.
Clin Exp Immunol. 2015 Nov;182(2):230-40. doi: 10.1111/cei.12669. Epub 2015 Aug 28.
Intracellular metabolic pathways dependent upon the mammalian target of rapamycin (mTOR) play a key role in immune-tolerance control. In this study, we focused on long-term mTOR-dependent immune-modulating effects in kidney transplant recipients undergoing conversion from calcineurin inhibitors (CNI) to mTOR inhibitors (everolimus) in a 1-year follow-up. The conversion to everolimus is associated with a decrease of neutrophils and of CD8(+) T cells. In addition, we observed a reduced production of interferon (IFN)-γ by CD8(+) T cells and of interleukin (IL)-17 by CD4(+) T lymphocytes. An increase in CD4(+) CD25(+) forkhead box protein 3 (FoxP3)(+) [regulatory T cell [(Treg)] numbers was also seen. Treg increase correlated with a higher proliferation rate of this regulatory subpopulation when compared with the CD4(+) FoxP3(-) effector counterpart. Basal phosphorylation level of S6 kinase, a major mTOR-dependent molecular target, was substantially maintained in patients treated with everolimus. Moreover, oscillations in serum concentration of everolimus were associated with changes in basal and activation-dependent S6 kinase phosphorylation of CD4(+) and CD8(+) T cells. Indeed, T cell receptor (TCR) triggering was observed to induce significantly higher S6 kinase phosphorylation in the presence of lower everolimus serum concentrations. These results unveil the complex mTOR-dependent immune-metabolic network leading to long-term immune-modulation and might have relevance for novel therapeutic settings in kidney transplants.
依赖哺乳动物雷帕霉素靶蛋白(mTOR)的细胞内代谢途径在免疫耐受控制中起关键作用。在本研究中,我们聚焦于在1年随访期内从钙调神经磷酸酶抑制剂(CNI)转换为mTOR抑制剂(依维莫司)的肾移植受者中,mTOR依赖性的长期免疫调节作用。转换为依维莫司与中性粒细胞及CD8(+) T细胞数量减少有关。此外,我们观察到CD8(+) T细胞产生的干扰素(IFN)-γ及CD4(+) T淋巴细胞产生的白细胞介素(IL)-17减少。CD4(+) CD25(+) 叉头框蛋白3(FoxP3)(+) [调节性T细胞 [(Treg)] 数量也增加。与CD4(+) FoxP3( -) 效应细胞亚群相比,Treg增加与该调节亚群更高的增殖率相关。在接受依维莫司治疗的患者中,主要的mTOR依赖性分子靶点S6激酶的基础磷酸化水平基本维持。此外,依维莫司血清浓度的波动与CD4(+) 和CD8(+) T细胞基础及激活依赖性S6激酶磷酸化的变化有关。实际上,在依维莫司血清浓度较低时,观察到T细胞受体(TCR)触发可诱导显著更高的S6激酶磷酸化。这些结果揭示了导致长期免疫调节的复杂的mTOR依赖性免疫代谢网络,可能与肾移植的新型治疗方案相关。